Ipsen, BioMérieux Partner on Theranostics Approach to Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ipsen and BioMérieux today announced a collaboration using a theranostics approach to focus on hormone-dependent cancers.

The two French firms will combine their expertise and resources to co-develop therapeutics and companion diagnostic tests. The collaboration will leverage Ipsen's broad portfolio of compounds and BioMérieux's diagnostic tests and focus on prostate and breast cancers, neuroendocrine tumors, and pituitary tomors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.